These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 25075090)

  • 1. Novel treatment strategies for cancer and their tumor-targeting approaches using antibodies against tumor-associated antigens.
    Kuroki M; Shirasu N
    Anticancer Res; 2014 Aug; 34(8):4481-8. PubMed ID: 25075090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical perspectives of bispecific antibodies in cancer.
    de Gast GC; van de Winkel JG; Bast BE
    Cancer Immunol Immunother; 1997; 45(3-4):121-3. PubMed ID: 9435853
    [No Abstract]   [Full Text] [Related]  

  • 3. Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER/MET crosstalk.
    Hu S; Fu W; Xu W; Yang Y; Cruz M; Berezov SD; Jorissen D; Takeda H; Zhu W
    Cancer Res; 2015 Jan; 75(1):159-70. PubMed ID: 25371409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Manipulation of regulatory T cells and antigen-specific cytotoxic T lymphocyte-based tumour immunotherapy.
    Karimi S; Chattopadhyay S; Chakraborty NG
    Immunology; 2015 Feb; 144(2):186-96. PubMed ID: 25243729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antibody-drug conjugates: an emerging modality for the treatment of cancer.
    Leal M; Sapra P; Hurvitz SA; Senter P; Wahl A; Schutten M; Shah DK; Haddish-Berhane N; Kabbarah O
    Ann N Y Acad Sci; 2014 Aug; 1321():41-54. PubMed ID: 25123209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current status of cancer immunotherapy.
    Kono K
    J Stem Cells Regen Med; 2014; 10(1):8-13. PubMed ID: 25075156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Generation of antibodies against membrane proteins.
    Hamakubo T; Kusano-Arai O; Iwanari H
    Biochim Biophys Acta; 2014 Nov; 1844(11):1920-1924. PubMed ID: 25135856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adaptive immunity in cancer immunology and therapeutics.
    Spurrell EL; Lockley M
    Ecancermedicalscience; 2014; 8():441. PubMed ID: 25075215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purified anti-CD3 × anti-HER2 bispecific antibody potentiates cytokine-induced killer cells of poor spontaneous cytotoxicity against breast cancer cells.
    He Q; Zhang H; Wang Y; Ting HH; Yu W; Cao X; Ge W
    Cell Biosci; 2014; 4(1):70. PubMed ID: 25485089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific T-cell engagers for cancer immunotherapy.
    Huehls AM; Coupet TA; Sentman CL
    Immunol Cell Biol; 2015 Mar; 93(3):290-6. PubMed ID: 25367186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific antibody platforms for cancer immunotherapy.
    Lameris R; de Bruin RC; Schneiders FL; van Bergen en Henegouwen PM; Verheul HM; de Gruijl TD; van der Vliet HJ
    Crit Rev Oncol Hematol; 2014 Dec; 92(3):153-65. PubMed ID: 25195094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Doxorubicin-Loaded Microrobots for Targeted Drug Delivery and Anticancer Therapy.
    Mallick S; Abouomar R; Rivas D; Sokolich M; Kirmizitas FC; Dutta A; Das S
    Adv Healthc Mater; 2023 Nov; 12(28):e2300939. PubMed ID: 37378647
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B cells, plasma cells and antibody repertoires in the tumour microenvironment.
    Sharonov GV; Serebrovskaya EO; Yuzhakova DV; Britanova OV; Chudakov DM
    Nat Rev Immunol; 2020 May; 20(5):294-307. PubMed ID: 31988391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent Development and Clinical Application of Cancer Vaccine: Targeting Neoantigens.
    Pan RY; Chung WH; Chu MT; Chen SJ; Chen HC; Zheng L; Hung SI
    J Immunol Res; 2018; 2018():4325874. PubMed ID: 30662919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Production and Evaluation of Specific Single-Chain Antibodies against CTLA-4 for Cancer-Targeted Therapy.
    Hosseinzadeh F; Mohammadi S; Nejatollahi F
    Rep Biochem Mol Biol; 2017 Oct; 6(1):8-14. PubMed ID: 29090224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. State of the art in anti-cancer mAbs.
    Chiavenna SM; Jaworski JP; Vendrell A
    J Biomed Sci; 2017 Feb; 24(1):15. PubMed ID: 28219375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in predictions of ODE models of tumor growth: a cautionary example.
    Murphy H; Jaafari H; Dobrovolny HM
    BMC Cancer; 2016 Feb; 16():163. PubMed ID: 26921070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic Adenovirus: Strategies and Insights for Vector Design and Immuno-Oncolytic Applications.
    Uusi-Kerttula H; Hulin-Curtis S; Davies J; Parker AL
    Viruses; 2015 Nov; 7(11):6009-42. PubMed ID: 26610547
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Construction of Anti-CD20 Single-Chain Antibody-CD28-CD137-TCRζ Recombinant Genetic Modified T Cells and its Treatment Effect on B Cell Lymphoma.
    Chen F; Fan C; Gu X; Zhang H; Liu Q; Gao X; Lu J; He B; Lai X
    Med Sci Monit; 2015 Jul; 21():2110-5. PubMed ID: 26195067
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.